FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386101213> ?p ?o ?g. }

• W4386101213 endingPage "e768020b" @default.
• W4386101213 startingPage "e768020b" @default.
• W4386101213 abstract "Topic: 3. Acute myeloid leukemia - Biology & Translational Research Background: Acute myeloid leukemia (AML) is a malignancy of hematopoetic tissue which occurs due to a halt in differentiation, loss of proliferation control and dysregulated apoptosis of myeloid progenitor cells. It is the most common acute leukemia in adults, accounting for 80% of all cases. Stratification of AML patients is based on their karyotype. However, the constant introduction of new molecular markers of prognosis of AML patients calls for a different approach. In many cancers, as well as AML, dysregulation of apoptosis constitutes the basis of pathogenesis and this phenomenon is important to consider when the success of chemotherapy is in question. Another important factor of chemotherapy success is the degree of drug efflux. These factors constitute tumor resistance. Pharmacotranscriptomic markers of tumor resistance could be important targets for specific therapy, which, when applied, could improve prognosis in AML. The anti-apoptotic gene BCL2 (B-cell lymphoma protein 2) and the pro-apoptotic BAX (BCL2-associated X) expression levels are markers of non-pump tumor resistance (genes associated with apoptosis), while a marker of tumor pump resistance (gene which codes a protein associated with drug efflux) is the expression level of MDR1 (multi-drug resistance gene 1). These tumor resistance markers could have a significant impact on AML prognosis. Aims: By analyzing the gene expression profiles of BCL2, BAX and MDR1 and using statistics to identify association with clinical indicators of prognosis in adult AML patients with normal karyotype (AML-NK), the significance of these genes as molecular targets can be further elucidated. Methods: Bone-marrow samples at diagnosis were collected from 51 adult patients with AML-NK, who were treated with the same 3 + 7 protocol, followed by three consolidation cycles. Expressions of BCL2, BAX and MDR1 were analyzed using the real-time polymerase chain reaction method. Clinical data and expression values were statistically evaluated for possible associations Results: The presence of chemoresistance was found to be associated with overexpression of BCL2 (BCL2+) (p=0.018), while underexpression of BAX in patients has shown a greater affinity towards relapse (p=0.034). Evaluating the expressions of BCL2 and BAX in a combined effect has shown that 87% of patients with BAX/BCL2low status were resistant to therapy (p=0.024). BCL2+ status was associated with high expression of MDR1 (p<0.001). Likewise, high expression of MDR1 was associated with the absence of NPM1 and FLT3-ITD mutations (p=0.048 and p=0.010, respectively). Summary/Conclusion: This is the first study that focused only on AML-NK patients, when it comes to analysis of BCL2, BAX and MDR1 gene expression profiles. The results of this preliminary study have shown that high BCL2 expression would likely lead to tumor resistance from chemotherapy, making anti-BCL2 treatment a viable option in patients with this expression profile. A study on a larger group of patients could clarify the prognostic importance of the studied pharmacotranscriptomics markers, contributing to a creation of personalized treatment of adult AML-NK patients. Keywords: MDR1, Acute myeloid leukemia, Bax, BCL2" @default.
• W4386101213 created "2023-08-24" @default.
• W4386101213 creator A5021945483 @default.
• W4386101213 creator A5035862716 @default.
• W4386101213 creator A5046586825 @default.
• W4386101213 creator A5049661945 @default.
• W4386101213 creator A5072824911 @default.
• W4386101213 creator A5084721756 @default.
• W4386101213 creator A5090286565 @default.
• W4386101213 date "2023-08-01" @default.
• W4386101213 modified "2023-09-26" @default.
• W4386101213 title "PB1776: EXPRESSION OF BCL2, BAX AND MDR1 GENES AS PHARMACOTRANSCRIPTOMIC MARKERS OF PROGNOSIS IN DE NOVO PATIENTS OF ADULT ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE" @default.
• W4386101213 doi "https://doi.org/10.1097/01.hs9.0000973960.76802.0b" @default.
• W4386101213 hasPublicationYear "2023" @default.
• W4386101213 type Work @default.
• W4386101213 citedByCount "0" @default.
• W4386101213 crossrefType "journal-article" @default.
• W4386101213 hasAuthorship W4386101213A5021945483 @default.
• W4386101213 hasAuthorship W4386101213A5035862716 @default.
• W4386101213 hasAuthorship W4386101213A5046586825 @default.
• W4386101213 hasAuthorship W4386101213A5049661945 @default.
• W4386101213 hasAuthorship W4386101213A5072824911 @default.
• W4386101213 hasAuthorship W4386101213A5084721756 @default.
• W4386101213 hasAuthorship W4386101213A5090286565 @default.
• W4386101213 hasBestOaLocation W43861012131 @default.
• W4386101213 hasConcept C114851261 @default.
• W4386101213 hasConcept C126322002 @default.
• W4386101213 hasConcept C143998085 @default.
• W4386101213 hasConcept C203014093 @default.
• W4386101213 hasConcept C2776694085 @default.
• W4386101213 hasConcept C2776863199 @default.
• W4386101213 hasConcept C2778461978 @default.
• W4386101213 hasConcept C2778729363 @default.
• W4386101213 hasConcept C2779399171 @default.
• W4386101213 hasConcept C502942594 @default.
• W4386101213 hasConcept C54355233 @default.
• W4386101213 hasConcept C71924100 @default.
• W4386101213 hasConcept C86803240 @default.
• W4386101213 hasConceptScore W4386101213C114851261 @default.
• W4386101213 hasConceptScore W4386101213C126322002 @default.
• W4386101213 hasConceptScore W4386101213C143998085 @default.
• W4386101213 hasConceptScore W4386101213C203014093 @default.
• W4386101213 hasConceptScore W4386101213C2776694085 @default.
• W4386101213 hasConceptScore W4386101213C2776863199 @default.
• W4386101213 hasConceptScore W4386101213C2778461978 @default.
• W4386101213 hasConceptScore W4386101213C2778729363 @default.
• W4386101213 hasConceptScore W4386101213C2779399171 @default.
• W4386101213 hasConceptScore W4386101213C502942594 @default.
• W4386101213 hasConceptScore W4386101213C54355233 @default.
• W4386101213 hasConceptScore W4386101213C71924100 @default.
• W4386101213 hasConceptScore W4386101213C86803240 @default.
• W4386101213 hasIssue "S3" @default.
• W4386101213 hasLocation W43861012131 @default.
• W4386101213 hasOpenAccess W4386101213 @default.
• W4386101213 hasPrimaryLocation W43861012131 @default.
• W4386101213 hasRelatedWork W2013647965 @default.
• W4386101213 hasRelatedWork W2161603182 @default.
• W4386101213 hasRelatedWork W2345640867 @default.
• W4386101213 hasRelatedWork W2348952709 @default.
• W4386101213 hasRelatedWork W2350274480 @default.
• W4386101213 hasRelatedWork W2358206108 @default.
• W4386101213 hasRelatedWork W2384872902 @default.
• W4386101213 hasRelatedWork W2393383561 @default.
• W4386101213 hasRelatedWork W2394313917 @default.
• W4386101213 hasRelatedWork W2936131736 @default.
• W4386101213 hasVolume "7" @default.
• W4386101213 isParatext "false" @default.
• W4386101213 isRetracted "false" @default.
• W4386101213 workType "article" @default.